@article {Pathak:May 2004:1477-9072:393,
	author = "Pathak, Atul",
	author = "Senard, Jean-Michel",
	title = "Pharmacology of orthostatic hypotension in Parkinsons disease: from pathophysiology to management",
	journal = "Expert Review of Cardiovascular Therapy",
	volume = "2",
	year = "May 2004",
	abstract = "Orthostatic hypotension is highly prevalent in the elderly, and affects up to 20% of patients with Parkinson&#8217;s disease. Pharmacological approaches help to demonstrate that Parkinson&#8217;s disease is a primary autonomic failure with involvement of the peripheral autonomic nervous system as shown by decreased [<SUP>123</SUP>I] meta-iodobenzylguanidine cardiac uptake and preserved growth hormone response to clonidine. No specific clinical trial has evaluated efficacy of antihypotensive drugs in Parkinson&#8217;s disease. End point of treatment should be a reduction in postural symptoms. Midodrine (Proamatin<SUP>&#174;</SUP>, Roberts Pharmaceutical), a vasoconstrictor and fludrocortisone (Florinef<SUP>&#174;</SUP>, Bristol&#8211;Myers Squibb), a volume expander are first choice drugs. No data are available on their effects on orthostatic hypotension-related morbidity. The usefulness of other drugs remains to be demonstrated. This review will highlight the importance of nonpharmacological measures in the management of orthostatic hypotension in Parkinson&#8217;s disease.",
	pages = "393-403(11)",
	url = "http://www.ingentaconnect.com/content/ftd/erc/2004/00000002/00000003/art00009"
	doi = "doi:10.1586/14779072.2.3.393"
}